PD-L1 >= 1%

About

Biomarker Type: Protein expression

Present: True

Marker: PD-L1

Unit: Tumor Proportion Score (TPS)

Equality: >=

Value: 0.01


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Durvalumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
Sensitivity (+) PD-L1 >= 1% Bladder Urothelial Carcinoma Nivolumab
Sensitivity (+) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Ipilimumab, Nivolumab
Sensitivity (+) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
Sensitivity (+) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Ipilimumab, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Durvalumab
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
Sensitivity (+) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
Sensitivity (+) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
Sensitivity (+) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Nivolumab, Oxaliplatin
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Nivolumab
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Durvalumab